28234672|t|Vascular smooth muscle cell peroxisome proliferator-activated receptor γ protects against endothelin-1 - induced oxidative stress and inflammation
28234672|a|Peroxisome proliferator-activated receptor γ (PPARγ) agonists reduce blood pressure and vascular injury in hypertensive rodents. Pparγ inactivation in vascular smooth muscle cells (VSMC) enhances vascular injury. Transgenic mice overexpressing endothelin (ET)-1 selectively in the endothelium (eET-1) exhibit endothelial dysfunction, increased oxidative stress and inflammation. We hypothesized that inactivation of the Pparγ gene in VSMC (smPparγ) would exaggerate ET-1 - induced vascular injury. eET-1, smPparγ and eET-1 / smPparγ mice were treated with tamoxifen for 5 days and studied 4 weeks later. SBP was higher in eET-1 and unaffected by smPparγ inactivation. Mesenteric artery vasodilatory responses to acetylcholine were impaired only in smPparγ. N-Nitro-L-arginine methyl ester abrogated relaxation responses, and the Ednra / Ednrb mRNA ratio was decreased in eET-1 / smPparγ, which could indicate that nitric oxide production was enhanced by ET-1 stimulation of endothelin type B receptors. Mesenteric artery media / lumen was greater only in eET-1 / smPparγ. Mesenteric artery reactive oxygen species increased in smPparγ and were further enhanced in eET-1 / smPparγ. Perivascular fat monocyte / macrophage infiltration was higher in eET-1 and smPparγ and increased further in eET-1 / smPparγ. Spleen CD11b cells were increased in smPparγ and further enhance d in eET-1 / smPparγ, whereas Ly-6C monocytes increased in eET-1 and smPparγ but not in eET-1 / smPparγ. Spleen T regulatory lymphocytes increased in smPparγ and decreased in eET-1, and decreased further in eET-1 / smPparγ. VSMC Pparγ inactivation exaggerates ET-1 - induced vascular injury, supporting a protective role for PPARγ in hypertension through modulation of pro-oxidant and proinflammatory pathways. Paradoxically, ET-1 overexpression preserved endothelial function in smPparγ mice, presumably by enhancing nitric oxide through stimulation of endothelin type B receptors.
28234672	0	27	Vascular smooth muscle cell	T025	C4082861
28234672	28	72	peroxisome proliferator-activated receptor γ	T116,T192	C0166417
28234672	90	102	endothelin-1	T116,T123	C0079281
28234672	105	112	induced	T169	C0205263
28234672	113	129	oxidative stress	T049	C0242606
28234672	134	146	inflammation	T046	C0021368
28234672	147	191	Peroxisome proliferator-activated receptor γ	T116,T192	C0166417
28234672	193	198	PPARγ	T116,T192	C0166417
28234672	200	208	agonists	T121	C0243192
28234672	209	215	reduce	T080	C0392756
28234672	216	230	blood pressure	T040	C0005823
28234672	235	250	vascular injury	T037	C0178324
28234672	254	266	hypertensive	T033	C0857121
28234672	267	274	rodents	T015	C0035804
28234672	276	281	Pparγ	T116,T192	C0166417
28234672	282	294	inactivation	T044	C0314679
28234672	298	326	vascular smooth muscle cells	T025	C4082861
28234672	328	332	VSMC	T025	C4082861
28234672	334	342	enhances	T052	C2349975
28234672	343	358	vascular injury	T037	C0178324
28234672	360	375	Transgenic mice	T015	C0025936
28234672	376	390	overexpressing	T045	C1171362
28234672	391	408	endothelin (ET)-1	T116,T123	C0079281
28234672	428	439	endothelium	T024	C0014257
28234672	440	447	(eET-1)	T116,T123	C0079281
28234672	456	479	endothelial dysfunction	T047	C0856169
28234672	481	490	increased	T081	C0205217
28234672	491	507	oxidative stress	T049	C0242606
28234672	512	524	inflammation	T046	C0021368
28234672	529	541	hypothesized	T078	C1512571
28234672	547	559	inactivation	T044	C0314679
28234672	567	577	Pparγ gene	T028	C1335238
28234672	581	585	VSMC	T025	C4082861
28234672	587	594	smPparγ	T028	C1335238
28234672	602	612	exaggerate	T080	C0442801
28234672	613	617	ET-1	T116,T123	C0079281
28234672	620	627	induced	T169	C0205263
28234672	628	643	vascular injury	T037	C0178324
28234672	645	650	eET-1	T116,T123	C0079281
28234672	652	659	smPparγ	T116,T192	C0166417
28234672	664	669	eET-1	T116,T123	C0079281
28234672	672	679	smPparγ	T116,T192	C0166417
28234672	680	684	mice	T015	C0025929
28234672	690	697	treated	T033	C0332154
28234672	703	712	tamoxifen	T109,T121	C0039286
28234672	728	735	studied	T062	C2603343
28234672	751	754	SBP	T201	C0871470
28234672	759	765	higher	T080	C0205250
28234672	769	774	eET-1	T116,T123	C0079281
28234672	779	789	unaffected	T077	C2986417
28234672	793	800	smPparγ	T116,T192	C0166417
28234672	801	813	inactivation	T044	C0314679
28234672	815	832	Mesenteric artery	T023	C0025465
28234672	833	845	vasodilatory	T042	C0042401
28234672	846	855	responses	T032	C0871261
28234672	859	872	acetylcholine	T109,T121,T123	C0001041
28234672	878	886	impaired	T169	C0221099
28234672	895	902	smPparγ	T116,T192	C0166417
28234672	904	935	N-Nitro-L-arginine methyl ester	T116,T123	C0083536
28234672	936	945	abrogated	T169	C3242341
28234672	946	956	relaxation	T052	C0035028
28234672	957	966	responses	T032	C0871261
28234672	976	981	Ednra	T028	C1414262
28234672	984	989	Ednrb	T028	C1414263
28234672	990	994	mRNA	T114,T123	C0035696
28234672	995	1000	ratio	T081	C0456603
28234672	1005	1014	decreased	T081	C0205216
28234672	1018	1023	eET-1	T116,T123	C0079281
28234672	1026	1033	smPparγ	T116,T192	C0166417
28234672	1047	1055	indicate	T078	C3146298
28234672	1061	1073	nitric oxide	T121,T123,T197	C0028128
28234672	1074	1084	production	T052	C1883254
28234672	1089	1097	enhanced	T052	C2349975
28234672	1101	1105	ET-1	T116,T123	C0079281
28234672	1106	1117	stimulation	T045	C0599177
28234672	1121	1148	endothelin type B receptors	T116,T192	C0218584
28234672	1150	1167	Mesenteric artery	T023	C0025465
28234672	1168	1173	media	T167	C1705217
28234672	1176	1181	lumen	T080	C1301906
28234672	1186	1193	greater	T081	C1704243
28234672	1202	1207	eET-1	T116,T123	C0079281
28234672	1210	1217	smPparγ	T116,T192	C0166417
28234672	1219	1236	Mesenteric artery	T023	C0025465
28234672	1237	1260	reactive oxygen species	T123,T196	C0162772
28234672	1261	1270	increased	T081	C0205217
28234672	1274	1281	smPparγ	T116,T192	C0166417
28234672	1299	1307	enhanced	T052	C2349975
28234672	1311	1316	eET-1	T116,T123	C0079281
28234672	1319	1326	smPparγ	T116,T192	C0166417
28234672	1328	1340	Perivascular	T082	C0442165
28234672	1341	1353	fat monocyte	T025	C0206131
28234672	1356	1366	macrophage	T025	C0024432
28234672	1367	1379	infiltration	T046	C0332448
28234672	1384	1390	higher	T080	C0205250
28234672	1394	1399	eET-1	T116,T123	C0079281
28234672	1404	1411	smPparγ	T116,T192	C0166417
28234672	1416	1425	increased	T081	C0205217
28234672	1437	1442	eET-1	T116,T123	C0079281
28234672	1445	1452	smPparγ	T116,T192	C0166417
28234672	1454	1460	Spleen	T023	C0037993
28234672	1461	1472	CD11b cells	T025	C1983879
28234672	1478	1487	increased	T081	C0205217
28234672	1491	1498	smPparγ	T116,T192	C0166417
28234672	1511	1518	enhance	T052	C2349975
28234672	1524	1529	eET-1	T116,T123	C0079281
28234672	1532	1539	smPparγ	T116,T192	C0166417
28234672	1549	1564	Ly-6C monocytes	T025	C0440752
28234672	1565	1574	increased	T081	C0205217
28234672	1578	1583	eET-1	T116,T123	C0079281
28234672	1588	1595	smPparγ	T116,T192	C0166417
28234672	1607	1612	eET-1	T116,T123	C0079281
28234672	1615	1622	smPparγ	T116,T192	C0166417
28234672	1624	1630	Spleen	T023	C0037993
28234672	1631	1655	T regulatory lymphocytes	T025	C0039198
28234672	1656	1665	increased	T081	C0205217
28234672	1669	1676	smPparγ	T116,T192	C0166417
28234672	1681	1690	decreased	T081	C0205216
28234672	1694	1699	eET-1	T116,T123	C0079281
28234672	1705	1714	decreased	T081	C0205216
28234672	1726	1731	eET-1	T116,T123	C0079281
28234672	1734	1741	smPparγ	T116,T192	C0166417
28234672	1743	1747	VSMC	T025	C4082861
28234672	1748	1753	Pparγ	T116,T192	C0166417
28234672	1754	1766	inactivation	T044	C0314679
28234672	1767	1778	exaggerates	T080	C0442801
28234672	1779	1783	ET-1	T116,T123	C0079281
28234672	1786	1793	induced	T169	C0205263
28234672	1794	1809	vascular injury	T037	C0178324
28234672	1835	1839	role	T077	C1705810
28234672	1844	1849	PPARγ	T116,T192	C0166417
28234672	1853	1865	hypertension	T047	C0020538
28234672	1874	1884	modulation	T082	C0443264
28234672	1888	1899	pro-oxidant	T123,T196	C0162772
28234672	1904	1919	proinflammatory	T169	C0333348
28234672	1920	1928	pathways	T044	C1704259
28234672	1945	1949	ET-1	T116,T123	C0079281
28234672	1950	1964	overexpression	T045	C1171362
28234672	1975	1986	endothelial	T024	C0014257
28234672	1987	1995	function	T169	C0542341
28234672	1999	2006	smPparγ	T116,T192	C0166417
28234672	2007	2011	mice	T015	C0025929
28234672	2027	2036	enhancing	T052	C2349975
28234672	2037	2049	nitric oxide	T121,T123,T197	C0028128
28234672	2058	2069	stimulation	T045	C0599177
28234672	2073	2100	endothelin type B receptors	T116,T192	C0218584